Siemens Medical Solutions and Gamma Medica Inc. this week announced that they will not renew their worldwide marketing agreement which included exclusive marketing rights for Siemens to market Gamma Medica's pre-clinical SPECT and SPECT/CT imaging products, according to a joint release.
   
Gamma Medica CEO Bradley Patt, PhD, indicated that though the market is expanding rapidly, the company's agreement had to be ended because of Siemens' impending purchase of CTI and also because of the existing overlap between the two companies' pre-clinical products, the companies said.